Author

No-Joon Song

h-index 6 View on Semantic Scholar

We have 2 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Developing Novel Bispecific T-cell Engager Therapy by Concurrent Targeting GARP on Cancer Cells and Regulatory T cells 2258672

It is demonstrated that elevated GARP expression in human tumors correlates with poor survival and higher relapse rates after first-line therapies after first-line therapies, and the Anti-GARP/CD3 platform holds the promise as a novel therapy of cancer immunotherapy worthy for clinical translation.

Ziyu Wang, Yaa S Amankwah, J. Mandula et al. · Journal of Immunology · 0 citations

Jul 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.

S. Vasu, N. Denlinger, No-Joon Song et al. · Blood Cancer Discovery · 0 citations